Risk factors for vascular dementia and Alzheimer disease

Stroke

Volumn 35, Issue 11 SUPPL. 1, 2004, Pages 2620-2622

  Gorelick, Philip B ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Alzheimer disease; Cognitive disorders; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; APOLIPOPROTEIN E4; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

AGE; ALZHEIMER DISEASE; ATHEROSCLEROSIS; BRAIN ATROPHY; BRAIN INFARCTION; CADASIL; CIGARETTE SMOKING; COGNITIVE DEFECT; CONFERENCE PAPER; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; FAT INTAKE; HEAD CIRCUMFERENCE; HEAD INJURY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMISPHERIC DOMINANCE; HEREDITY; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMOBILIZATION; METABOLIC SYNDROME X; MULTIINFARCT DEMENTIA; OBESITY; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK FACTOR; SEX DIFFERENCE; SOCIOECONOMICS; STROKE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THYROID DISEASE;

ALZHEIMER DISEASE; COGNITION DISORDERS; DEMENTIA, VASCULAR; HUMANS; RISK FACTORS;

EID: 7644223380     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000143318.70292.47     Document Type: Conference Paper

References (36)

1. Gorelick PB. Prevention. In: Bowler JV, Hachinski V, eds. Vascular Cognitive Impairment. Preventable Dementia. New York, NY: Oxford University Press; 2003: 308-320.
2. Gorelick PB. Prevention. In: Erkinjuntti T, Gauthier S, eds. Vascular Cognitive Impairment. London, UK: Martin Dunitz; 2002: 571-586.
3. Hachinski V. Vascular dementia: a radical redefinition. Dementia. 1994;5:130-132.
4. Snowden DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and clinical expression of Alzheimer's disease. The Nun Study. JAMA. 1997;277:813-817.
5. Gorelick PB, Nyenhuis D, Garron DC, and Cochran E. Is vascular dementia really Alzheimer's disease or mixed dementia? Neuroepidemiology. 1996;15:286-290.
6. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke. 2003;34:335-337.
7. Vagnucci AH, Li WW. Alzheimer's disease and angiogenesis. Lancet. 2003;361:605-608.
8. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62:1148-1155.
9. Gorelick PB, Erkinjuntti T, Hofman A, Rocca WA, Skoog I, Windblad B. Prevention of vascular dementia. Alz Dis Assoc Dis. 1999;13(Suppl 3):S131-S139.
10. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet. 2004;363:1139-1146.
11. Forette F, Seux M-L, Staessen JA, Thijs L, Babarskiene M-R, Babeanu S, Bossini A, Fagard R, Gil-Extremera B, Laks T, Kobalava Z, Sarti C, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Birkenhager WH; for the Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study [published correction in Arch Intern Med. 2003;163:241]. Arch Intern Med. 2002;162:2046-2052.
12. Gorelick PB. Can we save the brain from the ravages of midlife cardiovascular risk factors? Neurology. 1999;52:1114-1115.
13. Chui H. Vascular dementia, a new beginning. Shifting focus from clinical phenotype to ischemic brain injury. Neurol Clin. 2000;18:951-977.
14. Evans GJ. The epidemiology of the dementias of the elderly. In: Brody JA, Maddox GL, eds. Epidemiology and Aging. An International Perspective. New York, NY: Springer Publishing Company; 1988: 36-53.
15. Gorelick PB, Brody J, Cohen D, Freels S, Levy P, Dollear W, Forman H, Harris Y. Risk factors for dementia associated with multiple cerebral infarcts. A case-control analysis in predominantly African-American hospital-based patients. Arch Neurol. 1993;50:714-720.
16. Gorelick PB. Status of risk factors for dementia associated with stroke. Stroke. 1997;28:459-463.
17. Ritchie K, Lovestone S. The dementias. Lancet. 2002;360:1759-1766.
18. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease (genomic medicine). N Engl J Med. 2003;348:1356-1364.
19. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J; for the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women; the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
20. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; for the WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
21. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ; for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women; the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
22. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
23. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
24. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horowitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1234-1239.
25. in t'Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
26. Zandi PP, Anthony JC, Heyden KM, Mehta K, Mayer L, Breitner JCS; for the Cache County Study Investigators. Reduced incidence of AD with NSAID but not H2 receptor antagonists. The Cache County Study. Neruology. 2002;59:880-886.
27. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128.
28. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Farlow MR, Jin S, Thomas RG, Thal LJ; for the Alzheimer's Disease Cooperative Group. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. JAMA. 2003;289:2819-2826.
29. Report from the 6th Annual International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy on Use of Celecoxib vs. Placebo (abstract). Presented at: the 6th Annual International Stockholm/ Springfield Symposium on Advances in Alzheimer's Therapy; April 5-8, 2000; Stockholm, Sweeden.
30. McGeer PL, McGeer EG. Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 2001;58:1790-1792.
31. Mackenzie IRA. Anti-inflammatory drugs and Alzheimer-type pathology in aging. Arch Neurol. 2000;54:732-734.
32. Halliday GM, Shepherd CE, McCann H, Reid WGJ, Grayson DA, Broe GA, Kril JJ. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol. 2000;57:831-836.
33. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ for the Alzheimer's Disease Cooperative Study. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology. 2000;54:588-593.
34. Launer LJ. Nonsteroidal anti-inflammatory drugs and Alzheimer disease. What's next? JAMA. 2003;289:2865-2867.
35. Elias MF, Sullivan LM, D'Agostino RB, Elias PK, Beiser A, Au R, Seshadri S, DeCarli C, Wolf PA. Framingham Stroke Risk Profile and lowered cognitive performance. Stroke. 2004;35:404-409.
36. Strachan MWJ. Insulin and cognitive function. Lancet. 2003;362:1253.